Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2025-12-25 @ 10:25 PM
NCT ID:
NCT05011058
Pre Assignment Details:
Patients enrolled in the Peripheral T-Cell Lymphoma (Monotherapy) cohort who had stable disease at 6 weeks or disease progression at any time (confirmed by CT or MRI) were provided the option to cross over to receive combination therapy for the remainder of the study.
Recruitment Details:
Patients with Epstein-Barr virus (EBV)-associated lymphoid malignancy were nonrandomly assigned to one of 7 cohorts defined in the Study Description module, except the first 20 patients with peripheral T-cell lymphoma were randomized (1:1) to receive either combination nanatinostat plus valganciclovir therapy or nanatinostat monotherapy.
Up to 10 (Stage 1), up to 11 (Stage 2), and up to 120 (Expansion) patients were to be enrolled in each cohort depending on the number of responses observed.
Study:
NCT05011058
Study Brief:
Results Section:
NCT05011058